Global Human Papillomavirus Therapeutics Market

Human Papillomavirus Therapeutics Comprehensive Study by Route of Administration (Parenteral, Topical), Vaccine Type (Peptide-based Vaccines, Protein-based Vaccines, Viral-vectored vaccines, Bacterial-vectored vaccines, DNA-based vaccines), Indication (Cervical cancer, Anal cancer, Vaginal cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2028

Human Papillomavirus Therapeutics Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Human papillomavirus (HPV) is a viral infection that is passed between people through skin-to-skin contact. They are transmitted through sexual contact and can affect the genitals, mouth, or throat. HPV can also cause cervical cancer and other cancers of the genitals, head, neck, and throat. In addition, the increasing awareness about HPV and the strong efficacy of vaccines toward potentially preventing HPV from progressing into cancer or other indications are driving the growth of the market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies Profiled2A Pharma ApS (Denmark), Bavarian Nordic A/S (Denmark), BioVaxys Technology Corp. (Canada), F. Hoffmann-La Roche AG (Switzerland), Merck and Co. Inc. (United States), GlaxoSmithKline Plc (United Kingdom), ISA Pharmaceuticals BV (Netherlands), Serum Institute of India Pvt. Ltd. (India) and Walvax Biotechnology Co. Ltd. (China)


This growth is primarily driven by Increasing Prevalence of Sexual Transmitted Infection and Increasing Initiatives by Government & Private Organizations.

Globally, a noticeable market trend is evident Increasing Research and Development in HPV Major Players, such as 2A Pharma ApS (Denmark), Bavarian Nordic A/S (Denmark), BioVaxys Technology Corp. (Canada), F. Hoffmann-La Roche AG (Switzerland), Merck and Co. Inc. (United States), GlaxoSmithKline Plc (United Kingdom), ISA Pharmaceuticals BV (Netherlands), Serum Institute of India Pvt. Ltd. (India) and Walvax Biotechnology Co. Ltd. (China), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The launch of novel therapies is expected to increase the competition among vendors in the market and may result in vendor fragmentation during the forecast period. In order to differentiate their products from competitors and maintain market rivalry, vendors are also implementing a variety of development techniques. Apart from this, profitable acquisitions and mergers as well as mutual partnerships help firms maintain their competitive edge.

In June 2022, Roche announced the launch of human papillomavirus (HPV) self-sampling solution. This new solution enables a patient to privately collect samples for HPV screening. The clinically-validated vaginal sample is analyzed with the Roche cobas® HPV test and In June 2020, Merck known as MSD, announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for GARDASIL9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58

Regulatory Insights:
Centers for Disease Control and Prevention (CDC) is the regulatory body for Sexually transmitted diseases (STDs), this regulation can serve as facilitators to public health goals. CDC has various legal and policy resources, assessments, public health research, and policy reviews regarding TB, HIV, and other STDs.

Influencing Trend:
Increasing Research and Development in HPV

Market Growth Drivers:
Increasing Prevalence of Sexual Transmitted Infection and Increasing Initiatives by Government & Private Organizations

Challenges:
Lack of Awareness of HPV amongst Population

Restraints:
Limited Number of Treatment Option

Opportunities:
Development of Oral Vaccines for HPV

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Human Papillomavirus Therapeutics Market
- Analysis about New Entrants in Human Papillomavirus Therapeutics Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Human Papillomavirus Therapeutics Study Sheds Light on
— The Human Papillomavirus Therapeutics Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Human Papillomavirus Therapeutics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Human Papillomavirus Therapeutics industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Route of Administration
  • Parenteral
  • Topical

By Vaccine Type
  • Peptide-based Vaccines
  • Protein-based Vaccines
  • Viral-vectored vaccines
  • Bacterial-vectored vaccines
  • DNA-based vaccines

By Indication
  • Cervical cancer
  • Anal cancer
  • Vaginal cancer
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Sexual Transmitted Infection
      • 3.2.2. Increasing Initiatives by Government & Private Organizations
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness of HPV amongst Population
    • 3.4. Market Trends
      • 3.4.1. Increasing Research and Development in HPV
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Papillomavirus Therapeutics, by Route of Administration, Vaccine Type, Indication, Distribution Channel and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Human Papillomavirus Therapeutics (Value)
      • 5.2.1. Global Human Papillomavirus Therapeutics by: Route of Administration (Value)
        • 5.2.1.1. Parenteral
        • 5.2.1.2. Topical
      • 5.2.2. Global Human Papillomavirus Therapeutics by: Vaccine Type (Value)
        • 5.2.2.1. Peptide-based Vaccines
        • 5.2.2.2. Protein-based Vaccines
        • 5.2.2.3. Viral-vectored vaccines
        • 5.2.2.4. Bacterial-vectored vaccines
        • 5.2.2.5. DNA-based vaccines
      • 5.2.3. Global Human Papillomavirus Therapeutics by: Indication (Value)
        • 5.2.3.1. Cervical cancer
        • 5.2.3.2. Anal cancer
        • 5.2.3.3. Vaginal cancer
        • 5.2.3.4. Others
      • 5.2.4. Global Human Papillomavirus Therapeutics by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Human Papillomavirus Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Human Papillomavirus Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 2A Pharma ApS (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bavarian Nordic A/S (Denmark)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioVaxys Technology Corp. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck and Co. Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ISA Pharmaceuticals BV (Netherlands)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Serum Institute of India Pvt. Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Walvax Biotechnology Co. Ltd. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Human Papillomavirus Therapeutics Sale, by Route of Administration, Vaccine Type, Indication, Distribution Channel and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Human Papillomavirus Therapeutics (Value)
      • 7.2.1. Global Human Papillomavirus Therapeutics by: Route of Administration (Value)
        • 7.2.1.1. Parenteral
        • 7.2.1.2. Topical
      • 7.2.2. Global Human Papillomavirus Therapeutics by: Vaccine Type (Value)
        • 7.2.2.1. Peptide-based Vaccines
        • 7.2.2.2. Protein-based Vaccines
        • 7.2.2.3. Viral-vectored vaccines
        • 7.2.2.4. Bacterial-vectored vaccines
        • 7.2.2.5. DNA-based vaccines
      • 7.2.3. Global Human Papillomavirus Therapeutics by: Indication (Value)
        • 7.2.3.1. Cervical cancer
        • 7.2.3.2. Anal cancer
        • 7.2.3.3. Vaginal cancer
        • 7.2.3.4. Others
      • 7.2.4. Global Human Papillomavirus Therapeutics by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Human Papillomavirus Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Papillomavirus Therapeutics: by Route of Administration(USD Million)
  • Table 2. Human Papillomavirus Therapeutics Parenteral , by Region USD Million (2017-2022)
  • Table 3. Human Papillomavirus Therapeutics Topical , by Region USD Million (2017-2022)
  • Table 4. Human Papillomavirus Therapeutics: by Vaccine Type(USD Million)
  • Table 5. Human Papillomavirus Therapeutics Peptide-based Vaccines , by Region USD Million (2017-2022)
  • Table 6. Human Papillomavirus Therapeutics Protein-based Vaccines , by Region USD Million (2017-2022)
  • Table 7. Human Papillomavirus Therapeutics Viral-vectored vaccines , by Region USD Million (2017-2022)
  • Table 8. Human Papillomavirus Therapeutics Bacterial-vectored vaccines , by Region USD Million (2017-2022)
  • Table 9. Human Papillomavirus Therapeutics DNA-based vaccines , by Region USD Million (2017-2022)
  • Table 10. Human Papillomavirus Therapeutics: by Indication(USD Million)
  • Table 11. Human Papillomavirus Therapeutics Cervical cancer , by Region USD Million (2017-2022)
  • Table 12. Human Papillomavirus Therapeutics Anal cancer , by Region USD Million (2017-2022)
  • Table 13. Human Papillomavirus Therapeutics Vaginal cancer , by Region USD Million (2017-2022)
  • Table 14. Human Papillomavirus Therapeutics Others , by Region USD Million (2017-2022)
  • Table 15. Human Papillomavirus Therapeutics: by Distribution Channel(USD Million)
  • Table 16. Human Papillomavirus Therapeutics Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 17. Human Papillomavirus Therapeutics Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 18. Human Papillomavirus Therapeutics Online Pharmacies , by Region USD Million (2017-2022)
  • Table 19. South America Human Papillomavirus Therapeutics, by Country USD Million (2017-2022)
  • Table 20. South America Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 21. South America Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 22. South America Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 23. South America Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 24. Brazil Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 25. Brazil Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 26. Brazil Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 27. Brazil Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 28. Argentina Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 29. Argentina Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 30. Argentina Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 31. Argentina Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 32. Rest of South America Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 33. Rest of South America Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 34. Rest of South America Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 35. Rest of South America Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 36. Asia Pacific Human Papillomavirus Therapeutics, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 38. Asia Pacific Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 39. Asia Pacific Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 40. Asia Pacific Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 41. China Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 42. China Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 43. China Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 44. China Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 45. Japan Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 46. Japan Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 47. Japan Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 48. Japan Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 49. India Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 50. India Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 51. India Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 52. India Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 53. South Korea Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 54. South Korea Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 55. South Korea Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 56. South Korea Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 57. Taiwan Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 58. Taiwan Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 59. Taiwan Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 60. Taiwan Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 61. Australia Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 62. Australia Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 63. Australia Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 64. Australia Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 69. Europe Human Papillomavirus Therapeutics, by Country USD Million (2017-2022)
  • Table 70. Europe Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 71. Europe Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 72. Europe Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 73. Europe Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 74. Germany Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 75. Germany Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 76. Germany Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 77. Germany Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 78. France Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 79. France Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 80. France Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 81. France Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 82. Italy Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 83. Italy Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 84. Italy Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 85. Italy Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 86. United Kingdom Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 87. United Kingdom Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 88. United Kingdom Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 89. United Kingdom Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 90. Netherlands Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 91. Netherlands Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 92. Netherlands Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 93. Netherlands Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 94. Rest of Europe Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 95. Rest of Europe Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 96. Rest of Europe Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 97. Rest of Europe Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 98. MEA Human Papillomavirus Therapeutics, by Country USD Million (2017-2022)
  • Table 99. MEA Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 100. MEA Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 101. MEA Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 102. MEA Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 103. Middle East Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 104. Middle East Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 105. Middle East Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 106. Middle East Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 107. Africa Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 108. Africa Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 109. Africa Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 110. Africa Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 111. North America Human Papillomavirus Therapeutics, by Country USD Million (2017-2022)
  • Table 112. North America Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 113. North America Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 114. North America Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 115. North America Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 116. United States Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 117. United States Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 118. United States Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 119. United States Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 120. Canada Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 121. Canada Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 122. Canada Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 123. Canada Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 124. Mexico Human Papillomavirus Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 125. Mexico Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2017-2022)
  • Table 126. Mexico Human Papillomavirus Therapeutics, by Indication USD Million (2017-2022)
  • Table 127. Mexico Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2017-2022)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Human Papillomavirus Therapeutics: by Route of Administration(USD Million)
  • Table 138. Human Papillomavirus Therapeutics Parenteral , by Region USD Million (2023-2028)
  • Table 139. Human Papillomavirus Therapeutics Topical , by Region USD Million (2023-2028)
  • Table 140. Human Papillomavirus Therapeutics: by Vaccine Type(USD Million)
  • Table 141. Human Papillomavirus Therapeutics Peptide-based Vaccines , by Region USD Million (2023-2028)
  • Table 142. Human Papillomavirus Therapeutics Protein-based Vaccines , by Region USD Million (2023-2028)
  • Table 143. Human Papillomavirus Therapeutics Viral-vectored vaccines , by Region USD Million (2023-2028)
  • Table 144. Human Papillomavirus Therapeutics Bacterial-vectored vaccines , by Region USD Million (2023-2028)
  • Table 145. Human Papillomavirus Therapeutics DNA-based vaccines , by Region USD Million (2023-2028)
  • Table 146. Human Papillomavirus Therapeutics: by Indication(USD Million)
  • Table 147. Human Papillomavirus Therapeutics Cervical cancer , by Region USD Million (2023-2028)
  • Table 148. Human Papillomavirus Therapeutics Anal cancer , by Region USD Million (2023-2028)
  • Table 149. Human Papillomavirus Therapeutics Vaginal cancer , by Region USD Million (2023-2028)
  • Table 150. Human Papillomavirus Therapeutics Others , by Region USD Million (2023-2028)
  • Table 151. Human Papillomavirus Therapeutics: by Distribution Channel(USD Million)
  • Table 152. Human Papillomavirus Therapeutics Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 153. Human Papillomavirus Therapeutics Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 154. Human Papillomavirus Therapeutics Online Pharmacies , by Region USD Million (2023-2028)
  • Table 155. South America Human Papillomavirus Therapeutics, by Country USD Million (2023-2028)
  • Table 156. South America Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 157. South America Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 158. South America Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 159. South America Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 160. Brazil Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 161. Brazil Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 162. Brazil Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 163. Brazil Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 164. Argentina Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 165. Argentina Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 166. Argentina Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 167. Argentina Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 168. Rest of South America Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 169. Rest of South America Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 170. Rest of South America Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 171. Rest of South America Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 172. Asia Pacific Human Papillomavirus Therapeutics, by Country USD Million (2023-2028)
  • Table 173. Asia Pacific Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 174. Asia Pacific Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 175. Asia Pacific Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 176. Asia Pacific Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 177. China Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 178. China Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 179. China Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 180. China Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 181. Japan Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 182. Japan Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 183. Japan Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 184. Japan Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 185. India Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 186. India Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 187. India Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 188. India Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 189. South Korea Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 190. South Korea Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 191. South Korea Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 192. South Korea Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 193. Taiwan Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 194. Taiwan Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 195. Taiwan Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 196. Taiwan Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 197. Australia Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 198. Australia Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 199. Australia Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 200. Australia Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 205. Europe Human Papillomavirus Therapeutics, by Country USD Million (2023-2028)
  • Table 206. Europe Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 207. Europe Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 208. Europe Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 209. Europe Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 210. Germany Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 211. Germany Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 212. Germany Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 213. Germany Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 214. France Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 215. France Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 216. France Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 217. France Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 218. Italy Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 219. Italy Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 220. Italy Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 221. Italy Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 222. United Kingdom Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 223. United Kingdom Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 224. United Kingdom Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 225. United Kingdom Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 226. Netherlands Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 227. Netherlands Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 228. Netherlands Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 229. Netherlands Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 230. Rest of Europe Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 231. Rest of Europe Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 232. Rest of Europe Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 233. Rest of Europe Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 234. MEA Human Papillomavirus Therapeutics, by Country USD Million (2023-2028)
  • Table 235. MEA Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 236. MEA Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 237. MEA Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 238. MEA Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 239. Middle East Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 240. Middle East Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 241. Middle East Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 242. Middle East Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 243. Africa Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 244. Africa Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 245. Africa Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 246. Africa Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 247. North America Human Papillomavirus Therapeutics, by Country USD Million (2023-2028)
  • Table 248. North America Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 249. North America Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 250. North America Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 251. North America Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 252. United States Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 253. United States Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 254. United States Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 255. United States Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 256. Canada Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 257. Canada Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 258. Canada Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 259. Canada Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 260. Mexico Human Papillomavirus Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 261. Mexico Human Papillomavirus Therapeutics, by Vaccine Type USD Million (2023-2028)
  • Table 262. Mexico Human Papillomavirus Therapeutics, by Indication USD Million (2023-2028)
  • Table 263. Mexico Human Papillomavirus Therapeutics, by Distribution Channel USD Million (2023-2028)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Papillomavirus Therapeutics: by Route of Administration USD Million (2017-2022)
  • Figure 5. Global Human Papillomavirus Therapeutics: by Vaccine Type USD Million (2017-2022)
  • Figure 6. Global Human Papillomavirus Therapeutics: by Indication USD Million (2017-2022)
  • Figure 7. Global Human Papillomavirus Therapeutics: by Distribution Channel USD Million (2017-2022)
  • Figure 8. South America Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 10. Europe Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 11. MEA Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 12. North America Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 13. Global Human Papillomavirus Therapeutics share by Players 2022 (%)
  • Figure 14. Global Human Papillomavirus Therapeutics share by Players (Top 3) 2022(%)
  • Figure 15. Global Human Papillomavirus Therapeutics share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. 2A Pharma ApS (Denmark) Revenue, Net Income and Gross profit
  • Figure 18. 2A Pharma ApS (Denmark) Revenue: by Geography 2022
  • Figure 19. Bavarian Nordic A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 20. Bavarian Nordic A/S (Denmark) Revenue: by Geography 2022
  • Figure 21. BioVaxys Technology Corp. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. BioVaxys Technology Corp. (Canada) Revenue: by Geography 2022
  • Figure 23. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2022
  • Figure 25. Merck and Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck and Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 27. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 29. ISA Pharmaceuticals BV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 30. ISA Pharmaceuticals BV (Netherlands) Revenue: by Geography 2022
  • Figure 31. Serum Institute of India Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. Serum Institute of India Pvt. Ltd. (India) Revenue: by Geography 2022
  • Figure 33. Walvax Biotechnology Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 34. Walvax Biotechnology Co. Ltd. (China) Revenue: by Geography 2022
  • Figure 35. Global Human Papillomavirus Therapeutics: by Route of Administration USD Million (2023-2028)
  • Figure 36. Global Human Papillomavirus Therapeutics: by Vaccine Type USD Million (2023-2028)
  • Figure 37. Global Human Papillomavirus Therapeutics: by Indication USD Million (2023-2028)
  • Figure 38. Global Human Papillomavirus Therapeutics: by Distribution Channel USD Million (2023-2028)
  • Figure 39. South America Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 40. Asia Pacific Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 41. Europe Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 42. MEA Human Papillomavirus Therapeutics Share (%), by Country
  • Figure 43. North America Human Papillomavirus Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • 2A Pharma ApS (Denmark)
  • Bavarian Nordic A/S (Denmark)
  • BioVaxys Technology Corp. (Canada)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Merck and Co. Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • ISA Pharmaceuticals BV (Netherlands)
  • Serum Institute of India Pvt. Ltd. (India)
  • Walvax Biotechnology Co. Ltd. (China)
Additional players considered in the study are as follows:
Xiamen Innovax Biotech Co. Ltd. (China) , Inovio Pharmaceuticals Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 218 Pages 76 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Papillomavirus Therapeutics Market Quantitative research analysis
Global Human Papillomavirus Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Human Papillomavirus Therapeutics market are 2A Pharma ApS (Denmark), Bavarian Nordic A/S (Denmark), BioVaxys Technology Corp. (Canada), F. Hoffmann-La Roche AG (Switzerland), Merck and Co. Inc. (United States), GlaxoSmithKline Plc (United Kingdom), ISA Pharmaceuticals BV (Netherlands), Serum Institute of India Pvt. Ltd. (India) and Walvax Biotechnology Co. Ltd. (China), to name a few.
is dominating the Human Papillomavirus Therapeutics Market.
"Lack of Awareness of HPV amongst Population" is seen as one of the major challenges by many Industry Players of Human Papillomavirus Therapeutics Market
The Human Papillomavirus Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Human Papillomavirus Therapeutics market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Human Papillomavirus Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Neuropsychiatric Disorders And Treatment Comprehensive Study by Types (Degenerative Diseases, Psychosis, Neurotic Disorder), End Users (Hospitals, Specialty Clinics, Research & Development Centers, A...
$ 3800
Sepsis and Septic Shock Comprehensive Study by Type (Automated Diagnostics, Conventional Diagnostics), By End User (Hospitals, Pathology Center, Laboratories, Research Organization, Others), By Techn...
$ 3800
Upper-limb Robotic Neurorehabilitation Comprehensive Study by Type (Exoskeletons, End-effector Devices, Robotic Arms, Electrical Stimulation Devices, VR Systems, Others), By End User (Hospitals & Cli...
$ 3800
TMJ Disorders Comprehensive Study by Type (Muscular, Structural, Acute), Treatment (-Nonsurgical Treatments, Mouth Guards, Physical Therapy, Trigger Point Injections, Others, -Surgery, Arthrocentesis...
$ 3800
Hallux Rigidus Comprehensive Study by Treatment (-Non-Surgical Treatment, Shoe Modification, Orthotic Devices, Medications, Injection Therapy, Physical Therapy, -Surgical Treatment, Bone Spur Removal...
$ 3800
Teledermatology Comprehensive Study by Application (Direct consultations, Specialist referral, Online patient triage, Virtual prescription renewals, Patient follow-up care), Type (Synchronous, Asynch...
$ 3800